Board Name | Posts By alen121 | Post Created |
---|---|---|
SKTO SK3 Group Inc. | .25 CENTS BEFORE MARCH.. GO SKTO.. | 02/04/2014 3:09:33 PM |
TEVE Telvue Corp | I told you Seattle Broncos right .. | 02/02/2014 10:15:02 PM |
TEVE Telvue Corp | From Australia , Brancos.. | 02/02/2014 5:05:49 PM |
TEVE Telvue Corp | I will tell you one thing buddy.. W | 01/31/2014 8:51:44 PM |
SKTO SK3 Group Inc. | http://media.giphy.com/media/1jQhF | 01/31/2014 7:14:26 PM |
TEVE Telvue Corp | http://media.giphy.com/media/1jQhF | 01/31/2014 7:12:36 PM |
AEGY Alternative Energy Partners Inc. | http://img37.imageshack. | 01/31/2014 6:11:33 PM |
TEVE Telvue Corp | http://img37.imageshack. | 01/31/2014 6:09:44 PM |
SKTO SK3 Group Inc. | http://img37.imageshack. | 01/31/2014 6:08:58 PM |
SKTO SK3 Group Inc. | http://img37.imageshack. | 01/31/2014 6:07:39 PM |
TEVE Telvue Corp | Another 200 shares were shorted t | 01/31/2014 5:57:13 PM |
Recent Articles
- IDEX Biometrics ASA Announces Significant Share Issuance to Personnel
- Investors Urged to Join Class Action Against West Pharmaceutical Services
- Honoring Leonard A. Lauder: A Legacy in Alzheimer's Research
- Elevate Your Earnings with PFMCrypto's Exciting XRP Giveaway
- AIXA Miner Celebrates Groundbreaking Milestone in Green Mining
- Oma Savings Bank Plc Revises Profit Outlook: Important Update
- Transformative Leadership Change at Renault Group Announced
- Deadline for Fortrea Holdings Inc. Investors in Lawsuit Ahead
- Dupixent® Triumphs in Phase 4 Trial Against Xolair® for CRSwNP
- Dupixent vs. Xolair: Breakthrough Findings in Asthma Treatment
- Faruqi & Faruqi Investigates Ibotta's Legal Claims for Investors
- Red Cat Holdings Faces Legal Challenges Amid Investor Concerns
- Investor Alert: Key Updates on Iovance Biotherapeutics Lawsuit
- Investors Alert: Faruqi & Faruqi Advocate for Open Lending Claims
- Compass Diversified Investors Encouraged to Act Before Deadline
- Freedom Holding Corp. Sees Strong Financial Growth in 2025
- Intellia's Lonvo-z Shows Promising Results for HAE Treatment
- Important Update for Rocket Pharmaceuticals Investors
- DoubleVerify Investors Urged to Consider Legal Options Now
- Investing in Zenas BioPharma: What Investors Should Know
- Deadline for NET Power Investors: What's Next After Losses?
- Investors Urged to Act: Krispy Kreme Legal Investigation Update
- Investigating Investor Claims on Avis Budget Group's Financials
- Urgent Investor Insights: Fortrea Holdings Under Scrutiny
- Investor Alert: Examining West Pharmaceutical Services Fraud Claims
- Vital Insights on Napco Security Technologies for Investors
- Urgent Alert: Investors of PepGen Should Act Now
- Critical Update for Civitas Resources Investors Amid Legal Scrutiny
- UroGen Investors Urged to Act Before Class Action Deadline
- Understanding Legal Actions in Securities: Elevance Health Case
- Scatec Concludes Major Wind Power Deal in Egypt's Energy Future
- Scatec Secures Financing for Innovative Solar and Battery Project
- Uncovering Legal Pathways for Investors in Vestis Corporation
- AV-Comparatives Certifies Leading EDR and XDR Solutions for 2025
- Investors Encouraged to Act: Legal Options for Organon Losses
- Investors Alert: TechTarget Faces Class Action Investigation
- AV-Comparatives Unveils 2025 EDR Certification Results
- ZA Miner Unveils Cloud Mining Platform Capitalizing on Trends
- EQT Targets EUR 23 Billion Fund Size for Future Investments
- EQT Announces Ambitious Fund Size Target for EQT XI
- Redtiger Commemorates Five Years of Innovation with Discounts
- Revolutionizing Video Surveillance with AI Innovations
- Snoop Dogg Unveils TryDeathRow.com for a Fresh Cannabis Ride
- Understanding Verekitug's Potency in Fighting Inflammation
- Bitcoin Solaris Set for Major Launch with Exceptional Specs
- Advanced Epcoritamab Therapy Shows Promise for DLBCL Patients
- Vaultro Finance Celebrates Major Milestone in $VLT Token Sale
- Eve Air Mobility Partners with Revo for Urban Air Mobility Boost
- KIWI design Reaches Milestone with One Million Sold Head Straps
- Promising Results with Talquetamab and Teclistamab for Myeloma